Biotech Values

[WorstLuck]

SLRN

The risk is relatively low due to the strong balance sheet, as is the case for ENTA. The word, “extremely” in this context is not well-defined, so I don’t know about that.

I'm not following the company. However, my sense from respected people who do is that SLRN will be spending a good chunk of that cash on further development in TED and that there is no reason for them to do so.